Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A. Van Mourik is active.

Publication


Featured researches published by A. Van Mourik.


Radiotherapy and Oncology | 2016

EP-1577: A robust method to minimize geometric table rotational errors in stereotactic radiotherapy

J. Geuze; J. Kaas; T.A. Van de Water; A. Van Mourik; F. Wittkämper

S731 ________________________________________________________________________________ coverage and the conformity due to the dental implant for nasopharyngeal cancer(NPC) group (implant outside the PTV ).However, for the Non-NPC group (implant inside the PTV), a large discrepancy was obtained in all PTV parameters. There were statistically sig. differences(P<0.05) in PTVmax, PTVmean, Conformation Number and volume covered with 70Gy(V70Gy) among models.A large portion of PTV was underdosed.For the stainless steel, the V70Gy is below 70%, which is 25% poorer when compared with AAA plans. In the phantom study, ionization chamber and film measurements supported the dose perturbations by AXB. Using a 3% and 3mm criteria Gamma analysis, passing rate was between 95.0% and 99.7% demonstrating that AXB was in agreement with measurements in different models.


Radiotherapy and Oncology | 2016

EP-1680: Treatment planning of stereotactic radiosurgery for single brain metastases: impact of leaf width

E. Lamers-Kuijper; E. Van der Bijl; A. Van Mourik; C. Van Vliet-Vroegindeweij; E. Damen

ESTRO 35 2016 _____________________________________________________________________________________________________ Results: The mean GTV volumes ranged from 149.44 to 526.53 cc. VMAT plans show good results in comparison with 3DCRT in both conformity index (0.81±0.09 Vs 0.68±0.07 respectively, p-value of 0.009), and heterogeneity index (0.11±0.03 Vs 0.14±0.02, p value= 0.042). Furthermore, minimum doses to PTV in VMAT plans are higher than 3DCRT plans (57±1.22 Vs 55.1±0.86, p value= 0.001). In risk structures, the lung volume receiving 10Gy, 20Gy and 30Gy were reduced in VMAT plans (with relative reduction of 2.27%, p=0.002; 4.87%, p=0.001; 11.8% respectively). Mean lung dose was also reduced ( 15 Vs 17.69 ) but not statistically significant. V30 of the heart was reduced compared to 3DCRT (7.53±6.2 10.43±6.8 with p value of 0.051). The maximum dose of esophagus with VMAT was 47.7 Vs 48.69 with 3D CRT ( not statistically significant). Moreover, D 50 of the esophagus was less with VMAT ( 19.94 Vs 23.63) with p value of 0.22. Regarding monitor units, the mean values were ( 461.40±124.42 Vs 227.90±13.52) for VMAT and 3D CRT respectively.


Radiotherapy and Oncology | 2017

EP-1838: First IGRT results for SBRT bone and lymph node oligometastases within the pelvic region

L. Wiersema; Gerben R. Borst; S. Nakhaee; H. Peulen; T. Wiersma; M. Kwint; A. Smit; M. Romp; P. Remeijer; A. Van Mourik


International Journal of Radiation Oncology Biology Physics | 2009

Changes in Seroma Volume after Breast-conserving Surgery for Early Stage Breast Cancer: A Multi-institutional Analysis

T.J. Yang; Paula H.M. Elkhuizen; D. Minkema; Wilma D. Heemsbergen; A. Van Mourik; Jorien Cassee; Coen W. Hurkmans; C van Vliet-Vroegindeweij


Radiotherapy and Oncology | 2018

PO-0987: Target volume changes of brain metastases during fractionated SRS

E. Hessen; P. Damen; B. Jasperse; Luc Dewit; Paula H.M. Elkhuizen; A. Van Mourik; F. Wittkämper; E. Damen; U. Van der Heide; P. Hanssens; J. Schasfoort; Jasper Nijkamp; Gerben R. Borst


Radiotherapy and Oncology | 2018

EP-1813: End-to-end test with StereoPHAN to determine the accuracy of a stereotactic treatment chain

C. Panneman; J. Kaas; A.M. Olszewska; T.A. Van de Water; A. Van Mourik; F. Wittkämper


Radiotherapy and Oncology | 2018

EP-2375: Time dependence of intrafraction motion in SRS with mask fixation for linac and Gamma Knife ICON

J. Stam; A. Licup; P. Remeijer; A. Van Mourik


Radiotherapy and Oncology | 2018

EP-2336: Validation of VacFix for SBRT treatments of spine oligo metastasis

L. Wiersema; A. Licup; M. Buijs; A. Van Mourik; Gerben R. Borst; P. Remeijer


Photodiagnosis and Photodynamic Therapy | 2017

Optimizing the photodynamic therapy treatment approach for recurrent maxilla, sinonasal and anterior skull base malignancies

M.B. Karakullukçu; T.E.M. van Doeveren; R.L.P. van Veen; F. van der Boom; M. Smolic; A. Van Mourik; I.B. Tan


Radiotherapy and Oncology | 2016

OC-0160: Growth and oedema related shifts of brain metastasis treated with stereotactic radiosurgery

K. De Vries; M. Beerendonk; Luc Dewit; W. Boogerd; D. Brandsma; A. Van Mourik; Gerben R. Borst

Collaboration


Dive into the A. Van Mourik's collaboration.

Top Co-Authors

Avatar

Gerben R. Borst

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

P. Remeijer

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

E. Damen

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Paula H.M. Elkhuizen

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Coen W. Hurkmans

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

D. Minkema

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Luc Dewit

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar

Wilma D. Heemsbergen

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge